Mouse model and treatment of hereditary inclusion body myopathy
AssigneeHibm Research Group, Inc.
InventorsDaniel Kohan DARVISH, Yadira VALLES-AYOUB
Life of this patent
Estimating the term…
Loading patent…
AssigneeHibm Research Group, Inc.
InventorsDaniel Kohan DARVISH, Yadira VALLES-AYOUB
Estimating the term…
Disclosed herein are methods of treating HIBM in a subject comprising identifying subject in need thereof; and administering to the subject a compound, or a pharmaceutically acceptable salt, ester, amide, glycol, peptidyl, or prodrug thereof, wherein the compound is a compound that is biosynthesized in a wild type individual along a biochemical pathway between glucose and sialic acid, inclusive. Also disclosed herein are vectors comprising a nucleic acid sequence that encodes a polypeptide having at least 80% sequence identity to the sequence set forth in SEQ ID NO:2, recombinant cells comprising these vectors, and recombinant animals comprising the cells. In addition, methods of identifying a compound having therapeutic effect for HIBM are disclosed.
-20. (canceled)
A method of treating myopathy in a subject harboring one or more mutations in the gene encoding a bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE), comprising orally administering to the subject a composition comprising an effective amount of sialic acid or a pharmaceutically acceptable salt or prodrug thereof.
A method of treating myopathy in a subject, wherein the method comprises:
Dependencies are inferred from the claim text.